UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware13-5315170

(State of Incorporation)(I.R.S. Employer Identification No.)

66 Hudson Boulevard East, New York, New York 10001-2192

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Stock, $0.05 par valuePFENew York Stock Exchange

1.000% Notes due 2027PFE27New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes Nox

At May 3, 2024, 5,666,592,898 shares of the issuer s voting common stock were outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income

Condensed Consolidated Statements of Comprehensive Income

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Equity

Condensed Consolidated Statements of Cash Flows

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

36

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

54

Item 4.

Controls and Procedures

54

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

54

Item 1A.

Risk Factors

54

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

54

Item 3.

Defaults Upon Senior SecuritiesN/A

Item 4.

Mine Safety DisclosuresN/A

Item 5.

Other Information54

Item 6.

Exhibits

55

Signature

55

N/A = Not Applicable

DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 25, 2024 and February 26, 2023, and for U.S. subsidiaries is as of and for the three months ended March 31, 2024 and April 2, 2023. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2023 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:

2023 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2023

ALKanaplastic lymphoma kinase

Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ATTR-CMtransthyretin amyloid cardiomyopathy

BiohavenBiohaven Pharmaceutical Holding Company Limited

BioNTechBioNTech SE

BiopharmaGlobal Biopharmaceuticals Business

BMSBristol-Myers Squibb Company

BODBoard of Directors

CDCU.S. Centers for Disease Control and Prevention

Comirnaty*Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; and Comirnaty Omicron XBB.1.5.

COVID-19novel coronavirus disease of 2019

Developed MarketsIncludes, but is not limited to, the following markets: Western Europe, Japan, Central Europe, Canada, Scandinavian countries, Australia, South Korea, New Zealand, the Balkans and Finland

EMAEuropean Medicines Agency

Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, the Middle East, Eastern Europe (excluding the Balkans) and Turkey

EPS

earnings per share

ESGEnvironmental, Social and Governance

EUEuropean Union

EUAemergency use authorization

Exchange ActSecurities Exchange Act of 1934, as amended

FASBFinancial Accounting Standards Board

FDAU.S. Food and Drug Administration

Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024

GAAPGenerally Accepted Accounting Principles

GBTGlobal Blood Therapeutics, Inc.

GSKGSK plc

HaleonHaleon plc

HIPAAHealth Insurance Portability and Accountability Act of 1996

HospiraHospira, Inc.

HRR

homologous recombination repair

IPR&Din-process research and development

IRAInflation Reduction Act of 2022

IRSU.S. Internal Revenue Service

JVjoint venture

KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

LOEloss of exclusivity

mCRCmetastatic colorectal cancer

mCRPCmetastatic castration-resistant prostate cancer

mCSPCmetastatic castration-sensitive prostate cancer

MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations

MDLMulti-District Litigation

MeridianMeridian Medical Technologies, Inc.

Moody sMoody s Investors Service

mRNAmessenger ribonucleic acid

MylanMylan N.V.

NDA

New Drug Application

NimbusNimbus Therapeutics, LLC

nmCRPCnon-metastatic castration-resistant prostate cancer

nmCSPC

non-metastatic castration-sensitive prostate cancer

NSCLCnon-small cell lung cancer

ODToral disintegrating tablet

ORD

Oncology Research and Development

OTCover-the-counter

Paxlovid*an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)

PC1Pfizer CentreOne

PharmaciaPharmacia LLC (formerly Pharmacia Corporation)

PP&E

Property, plant and equipment

PRD

Pfizer Research and Development

Prevnar familyIncludes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)

PsApsoriatic arthritis

RArheumatoid arthritis

RCCrenal cell carcinoma

R&Dresearch and development

RSVrespiratory syncytial virus

S&PStandard & Poor s

SeagenSeagen Inc. and its subsidiaries

SECU.S. Securities and Exchange Commission

Takeda

Takeda Pharmaceutical Company Limited

UCulcerative colitis

U.K.United Kingdom

Upjohn BusinessPfizer s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris

U.S.United States

ViatrisViatris Inc.

ViiVViiV Healthcare Limited

Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac

*The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) and certain uses of Paxlovid have not been approved or licensed by the FDA. The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has been authorized for emergency use by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months through 11 years of age. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.

This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.

The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X (formerly known as Twitter) accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.

Certain of the products and product candidates discussed in this Form 10-Q are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS, EXCEPT PER SHARE DATA)March 31,

2024April 2,

2023

Revenues:

Product revenues(a)

$12,443 $16,221

Alliance revenues(a)

2,172 2,060

Royalty revenues(a)

263 204

Total revenues

14,879 18,486

Costs and expenses:

Cost of sales(b)

3,379 4,886

Selling, informational and administrative expenses(b)

3,495 3,418

Research and development expenses(b)

2,493 2,505

Acquired in-process research and development expenses 21

Amortization of intangible assets1,308 1,103

Restructuring charges and certain acquisition-related costs102 9

Other (income)/deductions net680 275

Income from continuing operations before provision/(benefit) for taxes on income

3,421 6,270

Provision/(benefit) for taxes on income

293 715

Income from continuing operations

3,128 5,555

Discontinued operations net of tax(5)1

Net income before allocation to noncontrolling interests

3,123 5,556

Less: Net income attributable to noncontrolling interests8 13

Net income attributable to Pfizer Inc. common shareholders

$3,115 $5,543

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders$0.55 $0.98

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

$0.55 $0.98

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders$0.55 $0.97

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

$0.55 $0.97

Weighted-average shares basic5,657 5,634

Weighted-average shares diluted5,697 5,727

(a)See Note 1A.

(b)Exclusive of amortization of intangible assets.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS)March 31,

2024April 2,

2023

Net income before allocation to noncontrolling interests

$3,123 $5,556

Foreign currency translation adjustments, net140 101

Unrealized holding gains/(losses) on derivative financial instruments, net217 2

Reclassification adjustments for (gains)/losses included in net income(a)

(12)303

205 305

Unrealized holding gains/(losses) on available-for-sale securities, net(51)87

Reclassification adjustments for (gains)/losses included in net income(b)

(14)(509)

(65)(422)

Reclassification adjustments related to amortization of prior service costs and other, net(28)(30)

Reclassification adjustments related to curtailments of prior service costs and other, net (5)

(28)(35)

Other comprehensive income/(loss), before tax251 (50)

Tax provision/(benefit) on other comprehensive income/(loss)53 (63)

Other comprehensive income/(loss) before allocation to noncontrolling interests$198 $12

Comprehensive income/(loss) before allocation to noncontrolling interests$3,321 $5,569

Less: Comprehensive income/(loss) attributable to noncontrolling interests3 10

Comprehensive income/(loss) attributable to Pfizer Inc.$3,319 $5,558

(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.

(b)Reclassified into Other (income)/deductions net.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS)March 31,

2024December 31, 2023

(Unaudited)

Assets

Cash and cash equivalents$719 $2,853

Short-term investments11,209 9,837

Trade accounts receivable, less allowance for doubtful accounts: 2024 $479; 2023 $470

10,989 11,566

Inventories10,892 10,189

Current tax assets4,233 3,978

Other current assets4,372 4,911

Total current assets42,415 43,333

Equity-method investments8,123 11,637

Long-term investments3,490 3,731

Property, plant and equipment, less accumulated depreciation: 2024 $16,362; 2023 $16,045

18,803 18,940

Identifiable intangible assets62,829 64,900

Goodwill69,297 67,783

Noncurrent deferred tax assets and other noncurrent tax assets4,942 3,706

Other noncurrent assets11,197 12,471

Total assets$221,095 $226,501

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2024 $1,001; 2023 $2,254

$8,232 $10,350

Trade accounts payable5,591 6,710

Dividends payable 2,372

Income taxes payable3,192 2,349

Accrued compensation and related items2,192 2,776

Deferred revenues2,502 2,700

Other current liabilities18,788 20,537

Total current liabilities40,497 47,794

Long-term debt61,307 61,538

Pension and postretirement benefit obligations2,076 2,167

Noncurrent deferred tax liabilities931 640

Other taxes payable8,603 8,534

Other noncurrent liabilities15,122 16,539

Total liabilities128,537 137,213

Commitments and Contingencies

Common stock480 478

Additional paid-in capital92,997 92,631

Treasury stock(114,755)(114,487)

Retained earnings121,318 118,353

Accumulated other comprehensive loss(7,758)(7,961)

Total Pfizer Inc. shareholders equity92,282 89,014

Equity attributable to noncontrolling interests276 274

Total equity92,558 89,288

Total liabilities and equity$221,095 $226,501

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20249,562 $478 $92,631 (3,916)$(114,487)$118,353 $(7,961)$89,014 $274 $89,288

Net income

3,115 3,115 8 3,123

Other comprehensive income/(loss), net of tax203 203 (5)198

Cash dividends declared, per share: $

Common stock

Share-based payment transactions30 1 366 (10)(268)(151)(51)(51)

Other

Balance, March 31, 20249,592 $480 $92,997 (3,925)$(114,755)$121,318 $(7,758)$92,282 $276 $92,558

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20239,519 $476 $91,802 (3,903)$(113,969)$125,656 $(8,304)$95,661 $256 $95,916

Net income

5,543 5,543 13 5,556

Other comprehensive income/(loss), net of tax15 15 (3)12

Cash dividends declared, per share: $

Common stock

Share-based payment transactions41 2 350 (12)(504)(97)(249)(249)

Other

Balance, April 2, 20239,560 $478 $92,153 (3,915)$(114,473)$131,102 $(8,289)$100,970 $266 $101,236

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended

(MILLIONS)March 31,

2024April 2,

2023

Operating Activities

Net income before allocation to noncontrolling interests$3,123 $5,556

Discontinued operations net of tax(5)1

Net income from continuing operations before allocation to noncontrolling interests3,128 5,555

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:

Depreciation and amortization1,736 1,487

Asset write-offs and impairments136 270

Deferred taxes(441)(598)

Share-based compensation expense220 105

Benefit plan contributions in excess of expense/income(201)(200)

Other adjustments, net(151)99

Other changes in assets and liabilities, net of acquisitions and divestitures(3,336)(5,507)

Net cash provided by/(used in) operating activities1,090 1,212

Investing Activities

Purchases of property, plant and equipment(704)(1,139)

Purchases of short-term investments(797)(6,665)

Proceeds from redemptions/sales of short-term investments658 6,400

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(1,187)4,665

Purchases of long-term investments(35)(51)

Proceeds from redemptions/sales of long-term investments305 124

Proceeds from partial sale of investment in Haleon(a)

3,491

Other investing activities, net (18)

Net cash provided by/(used in) investing activities1,732 3,315

Financing Activities

Proceeds from short-term borrowings1,444 11

Payments on short-term borrowings(328)

Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less

(2,039)226

Payments on long-term debt(1,250)(269)

Cash dividends paid(2,372)(2,303)

Other financing activities, net(386)(436)

Net cash provided by/(used in) financing activities(4,931)(2,771)

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

(28)(2)

Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents(2,137)1,754

Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period2,917 468

Cash and cash equivalents and restricted cash and cash equivalents, at end of period$780 $2,222

Supplemental Cash Flow Information

Cash paid during the period for:

Income taxes

$184 $329

Interest paid

415 419

Interest rate hedges33 60

(a) See Note 2B.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2023 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.

These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2023 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 25, 2024 and February 26, 2023, and for U.S. subsidiaries is as of and for the three months ended March 31, 2024 and April 2, 2023.

We manage our commercial operations through two operating segments, each led by a single manager: Biopharma and Business Innovation. Biopharma is the only reportable segment. See Note 13A.

We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for:

in the first quarter of 2024, we reclassified royalty income (substantially all of which is related to Biopharma) from Other (income)/deductions net and began presenting Royalty revenues as a separate line item within Total revenues in our consolidated statements of income, and reclassified the associated royalty receivables from Other current assets to Trade accounts receivable, less allowance for doubtful accounts in our consolidated balance sheet;

in the fourth quarter of 2023, we began presenting Product revenues and Alliance revenues as separate line items within Total revenues in our consolidated statements of income; and

segment reporting and geographic information in connection with the commercial reorganization that went into effect on January 1, 2024 (see Note 13).

Business development activities, including the December 2023 acquisition of Seagen, impacted financial results in the periods presented. See Note 2 below, as well as Notes 1A and 2 in our 2023 Form 10-K.

B. New Accounting Standard Adopted in 2024

On January 1, 2024, we adopted a new accounting standard which clarifies that contractual sale restrictions are not considered in measuring equity securities at fair value. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.

C. Revenues and Trade Accounts Receivable

Customers Our prescription biopharmaceutical products, with the exception of Paxlovid in 2023, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sold Paxlovid globally to government agencies in 2023. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain of our vaccines, including Comirnaty, are subject to seasonality of demand.

Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:

(MILLIONS)March 31,

2024December 31, 2023

Reserve against Trade accounts receivable, less allowance for doubtful accounts

$1,573 $1,770

Other current liabilities:

Accrued rebates5,880 5,546

Other accruals646 902

Other noncurrent liabilities

382 796

Total accrued rebates and other sales-related accruals$8,481 $9,014

Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience,

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.

In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.

During the three months ended March 31, 2024 and April 2, 2023, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2023 Form 10-K.

Note 2. Acquisition and Equity-Method Investment

A. Acquisition

Seagen On December 14, 2023 (the acquisition date), we acquired Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 per share in cash. The total fair value of the consideration transferred was $44.2 billion ($43.4 billion, net of cash acquired). The combination of certain Pfizer and Seagen entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps.

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, including adjustments made in the first quarter of 2024 (measurement period adjustments) with a corresponding change to goodwill. The estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as soon as possible but no later than one year from the acquisition date.

(MILLIONS)Amounts Recognized

as of Acquisition Date

(as previously reported as of December 31, 2023)

Measurement Period Adjustments(a)

Amounts Recognized as of Acquisition Date (as adjusted)

Working capital, excluding inventories

$736 $(159)$577

Inventories(b)

4,195 (891)3,304

Property, plant and equipment524 (239)285

Identifiable intangible assets, excluding in-process research and development(c)

7,970 (560)7,410

In-process research and development20,800 (100)20,700

Other noncurrent assets174 (94)80

Net income tax accounts

(6,123)468 (5,655)

Other noncurrent liabilities(167)51 (116)

Total identifiable net assets28,108 (1,524)26,584

Goodwill16,126 1,524 17,650

Net assets acquired/total consideration transferred$44,234 $ $44,234

(a)The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

(b)As adjusted, comprised of $1.2 billion current inventories and $2.1 billion noncurrent inventories.

(c)As adjusted, comprised mainly of $7.0 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.

The measurement period adjustments did not have a material impact on our earnings.

The following items are subject to change:

Amounts for certain balances included in working capital (excluding inventories), and certain legal contingencies, pending receipt of certain information that could affect provisional amounts recorded. We do not believe any adjustments for legal contingencies will have a material impact on our consolidated financial statements.

Amounts for identifiable intangible assets, inventories, contractual commitments, PP&E, and operating lease right-of-use assets and liabilities, pending finalization of valuation efforts, the completion of certain physical inventory counts and the confirmation of the physical existence and condition of certain PP&E assets.

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Amounts for income tax assets, receivables and liabilities, pending the filing of Seagen s pre-acquisition tax returns and the receipt of information, including but not limited to that from taxing authorities, which may change certain estimates and assumptions used.

The following table provides unaudited U.S. GAAP supplemental pro forma information as if the acquisition of Seagen had occurred on January 1, 2022:

Unaudited Supplemental Pro Forma Consolidated Results

Three Months Ended

(MILLIONS, EXCEPT PER SHARE DATA)April 2,

2023

Revenues$19,006

Net income attributable to Pfizer Inc. common shareholders

4,651

Diluted earnings per share attributable to Pfizer Inc. common shareholders

0.81

The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company s results of operations would have been had the acquisition occurred on January 1, 2022, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma adjustments reflected here due to many factors.

The unaudited supplemental pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of the assets acquired and the liabilities assumed from Seagen. The historical U.S. GAAP financial information of Pfizer and Seagen was adjusted, primarily for the following pre-tax adjustments for the three months ended April 2, 2023:

Additional amortization expense of approximately $142 million related to the preliminary estimate of the fair value of identifiable intangible assets acquired.

Additional expense related to the preliminary estimate of the fair value adjustment to acquisition-date inventory estimated to have been sold of approximately $224 million.

Additional estimated interest expense of approximately $488 million related to the debt issued by Pfizer and the commercial paper borrowings to partially finance the acquisition.

Elimination of interest income of approximately $67 million associated with money market funds under the assumption that a portion of these funds would have been liquidated to partially fund the acquisition.

The above adjustments were then adjusted for the applicable tax impact using an estimated weighted-average statutory tax rate applied to the applicable pro forma adjustments.

B. Equity-Method Investment

Haleon We owned 32% of Haleon as of December 31, 2023. In March 2024, we sold approximately 30% of our investment in Haleon through the sale of 791 million ordinary shares in a global public offering, and the sale of 102 million ordinary shares directly to Haleon for total consideration of $3.5 billion. We recognized a gain on the sale of our Haleon shares of $150 million during the first quarter of 2024 in Other (income)/deductions net (see Note 4). After the share sale, we owned approximately 23% of the outstanding voting shares of Haleon as of March 31, 2024.

The fair value of our investment in Haleon as of March 31, 2024, based on quoted market prices of Haleon stock, was $8.7 billion. Haleon is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. We record our share of earnings from Haleon on a quarterly basis on a one-quarter lag in Other (income)/deductions net.

12

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table summarizes the change in the carrying value of our investment in Haleon:

Three Months Ended

(MILLIONS)March 31,

2024April 2,

2023

Beginning carrying value reported in Equity-method investments

$11,451 $10,824

Carrying value of shares sold

(3,312)

Currency translation adjustments and other(a)

(132)89

Basis difference adjustments and amortization(b)

(100)

Pfizer share of Haleon earnings

15 68

Ending carrying value reported in Equity-method investments

$7,922 $10,980

(a)See Note 6.

(b)Equity-method basis difference adjustments and amortization included in Other (income)/deductions net. Adjustments are associated with the impact of Haleon s brand sales and impairments of intangible assets and changes in Haleon s tax rates on intangible asset-related deferred tax liabilities. See Note 4.

Summarized financial information for Haleon for the three months ending December 31, 2023, the most recent period available, and for the three months ending December 31, 2022, is as follows:

Three Months Ended

(MILLIONS)December 31,

2023December 31,

2022

Net sales$3,434 $3,261

Cost of sales(1,596)(1,496)

Gross profit$1,837 $1,766

Income from continuing operations60 225

Net income60 225

Income attributable to shareholders47 211

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

A. Realigning our Cost Base Program

In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. We expect costs associated with this multi-year effort to continue through 2024 and to total approximately $2.8 billion, primarily representing cash expenditures for severance and implementation costs, of which $2.3 billion is associated with our Biopharma segment. From the start of this program through March 31, 2024, we incurred costs under this program of $1.6 billion, of which $1.3 billion is associated with our Biopharma segment (substantially all of which represents restructuring charges).

13

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

B. Key Activities

The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:

Three Months Ended

(MILLIONS)March 31,

2024April 2,

2023

Restructuring charges/(credits):

Employee terminations$(29)$(36)

Asset impairments25 (10)

Exit costs

14 2

Restructuring charges/(credits)(a)

10 (44)

Transaction costs(b)

Integration costs and other(c)

87 52

Restructuring charges and certain acquisition-related costs102 9

Net periodic benefit costs/(credits) recorded in Other (income)/deductions net

3 (5)

Additional depreciation asset restructuring recorded in our condensed consolidated statements of income, mainly in Cost of sales(d)

4 18

Implementation costs recorded in our condensed consolidated statements of income as follows(e):

Cost of sales16 15

Selling, informational and administrative expenses29 59

Research and development expenses13 11

Total implementation costs58 85

Total costs associated with acquisitions and cost-reduction/productivity initiatives$168 $107

(a)In 2024, primarily represents Seagen acquisition-related costs, largely offset by cost-reduction initiatives. In 2023, primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: credits of $37 million for the three months ended March 31, 2024 and credits of $64 million for the three months ended April 2, 2023.

(b)Represents external costs for banking, legal, accounting and other similar services.

(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.

(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

The Biopharma segment information above reflects changes as a result of the reorganization in the first quarter of 2024 (see Note 13A).

The following summarizes the components and changes in restructuring accruals:

(MILLIONS)Employee

Termination

CostsAsset

Impairment

ChargesExit CostsAccrual

Balance, December 31, 2023(a)

$1,978 $ $11 $1,988

Provision/(credit)(29)25 14 10

Utilization and other(b)

(320)(25)(15)(360)

Balance, March 31, 2024(c)

$1,628 $ $10 $1,638

(a)Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).

(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.

(c)Included in Other current liabilities ($1.1 billion) and Other noncurrent liabilities ($519 million).

14

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 4. Other (Income)/Deductions Net

Components of Other (income)/deductions net include:

Three Months Ended

(MILLIONS)March 31,

2024April 2,

2023

Interest income$(129)$(177)

Interest expense790 318

Net interest expense(a)

661 141

Net (gains)/losses recognized during the period on equity securities(b)

(25)451

Income from collaborations, out-licensing arrangements and sales of compound/product rights (68)

Net periodic benefit costs/(credits) other than service costs(103)(80)

Certain legal matters, net(c)

208 36

Certain asset impairments(d)

109 264

Haleon equity method (income)/loss(e)

88 (68)

Other, net(f)

(258)(403)

Other (income)/deductions net$680 $275

(a)The increase in net interest expense in the first quarter of 2024 reflects (i) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as $8 billion of commercial paper issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen and (ii) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023.

(b)The net losses in the first quarter of 2023 include, among other things, unrealized losses of $363 million related to our investments in Cerevel Therapeutics Holdings, Inc. and BioNTech.

(c)The first quarters of 2024 and 2023 primarily include certain product liability expenses related to products discontinued and/or divested by Pfizer.

(d)The first quarter of 2024 represents intangible asset impairment charges associated with our Biopharma segment for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures. The first quarter of 2023 primarily represented intangible asset impairment charges, including $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts, and $120 million associated with our Biopharma segment resulting from the discontinuation of a study related to an out-licensed IPR&D asset for the treatment of prostate cancer.

(e)See Note 2B.

(f)The first quarter of 2024 primarily includes, among other things, a $150 million gain on the partial sale of our investment in Haleon and dividend income of $61 million from our investment in ViiV. The first quarter of 2023 primarily included, among other things, dividend income of $211 million from our investment in Nimbus resulting from Takeda s acquisition of Nimbus s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary, and $92 million from our investment in ViiV.

Additional information about the intangible assets that were impaired during 2024 follows:

Three Months Ended

Fair Value(a)

March 31, 2024

(MILLIONS)AmountLevel 1Level 2Level 3Impairment

Intangible assets Developed technology rights(b)

$102 $ $ $102 $109

(a)The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also Note 1E in our 2023 Form 10-K.

(b)Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Note 5. Tax Matters

A. Taxes on Income from Continuing Operations

Our effective tax rate for continuing operations was 8.6% for the first quarter of 2024, compared to 11.4% for the first quarter of 2023. The decrease in the effective tax rate for the first quarter of 2024, compared to the first quarter of 2023, was primarily due to a favorable change in the jurisdictional mix of earnings.

We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The sixth annual installment was paid by its April 15, 2024 due date and is reported in current Income taxes payable as of March 31, 2024. The remaining liability is reported in noncurrent Other taxes payable. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.

15

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

For the year ended December 31, 2023, our cash paid for income taxes, net of refunds, was $3.1 billion, of which $1.9 billion was paid in the U.S.

B. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.

The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, tax years 2016-2018 are under audit. Tax years 2019-2024 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2012.

See Note 5D in our 2023 Form 10-K.

C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)

Components of Tax provision/(benefit) on other comprehensive income/(loss) include:

Three Months Ended

(MILLIONS)March 31,

2024April 2,

2023

Foreign currency translation adjustments, net(a)

$25 $(25)

Unrealized holding gains/(losses) on derivative financial instruments, net45 3

Reclassification adjustments for (gains)/losses included in net income

(4)21

41 24

Unrealized holding gains/(losses) on available-for-sale securities, net(6)11

Reclassification adjustments for (gains)/losses included in net income

(2)(64)

(8)(53)

Reclassification adjustments related to amortization of prior service costs and other, net(5)(7)

Reclassification adjustments related to curtailments of prior service costs and other, net (1)

(5)(9)

Tax provision/(benefit) on other comprehensive income/(loss)$53 $(63)

(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.

Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests

The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:

Net Unrealized Gains/(Losses)Benefit Plans

(MILLIONS)Foreign Currency Translation Adjustments(a)

Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)

Balance, December 31, 2023

$(7,863)$(217)$(9)$128 $(7,961)

Other comprehensive income/(loss)(b)

120 164 (57)(24)203

Balance, March 31, 2024$(7,743)$(53)$(66)$104 $(7,758)

(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.

(b)Foreign currency translation adjustments include net gains related to the impact of our net investment hedging program and net losses related to our equity-method investment in Haleon (see Note 2B).

16

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Financial Instruments

A. Fair Value Measurements

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:

March 31, 2024December 31, 2023

(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2

Financial assets:

Short-term investments

Equity securities with readily determinable fair values:

Money market funds$2,483 $ $2,483 $5,124 $ $5,124

Available-for-sale debt securities:

Government and agency non-U.S.

5,214 5,214 817 817

Government and agency U.S.

1,958 1,958 2,601 2,601

Corporate and other

1,045 1,045 982 982

8,217 8,217 4,400 4,400

Total short-term investments10,700 10,700 9,524 9,524

Other current assets

Derivative assets:

Interest rate contracts

1 1

Foreign exchange contracts

390 390 298 298

Total other current assets391 391 298 298

Long-term investments

Equity securities with readily determinable fair values(a)

2,543 2,542 2,779 2,772 7

Available-for-sale debt securities:

Government and agency non-U.S.

131 131 124 124

Corporate and other

6 6 26 26

137 137 150 150

Total long-term investments2,680 2,542 138 2,929 2,772 156

Other noncurrent assets

Derivative assets:

Interest rate contracts

26 26 144 144

Foreign exchange contracts

364 364 258 258

Total derivative assets390 390 402 402

Insurance contracts(b)

853 853 790 790

Total other noncurrent assets1,243 1,243 1,191 1,191

Total assets$15,013 $2,542 $12,471 $13,943 $2,772 $11,170

Financial liabilities:

Other current liabilities

Derivative liabilities:

Interest rate contracts$17 $ $17 $16 $ $16

Foreign exchange contracts

117 117 404 404

Total other current liabilities134 134 420 420

Other noncurrent liabilities

Derivative liabilities:

Interest rate contracts346 346 275 275

Foreign exchange contracts

665 665 725 725

Total other noncurrent liabilities1,011 1,011 1,000 1,000

Total liabilities$1,146 $ $1,146 $1,420 $ $1,420

(a)Long-term equity securities of $115 million as of March 31, 2024 and $130 million as of December 31, 2023 were held in restricted trusts for U.S. non-qualified employee benefit plans.

(b)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).

Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion, was $61 billion as of March 31, 2024 and $62 billion as of December 31, 2023. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $60 billion as of March 31, 2024 and $61 billion as of December 31, 2023.

The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant

17

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

as of March 31, 2024 and December 31, 2023. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.

B. Investments

Total Short-Term, Long-Term and Equity-Method Investments

The following summarizes our investments by classification type:

(MILLIONS)March 31,

2024 December 31, 2023

Short-term investments

Equity securities with readily determinable fair values(a)

$2,483 $5,124

Available-for-sale debt securities8,217 4,400

Held-to-maturity debt securities510 313

Total Short-term investments$11,209 $9,837

Long-term investments

Equity securities with readily determinable fair values(b)

$2,543 $2,779

Available-for-sale debt securities137 150

Held-to-maturity debt securities45 47

Private equity securities at cost(b)

765 755

Total Long-term investments$3,490 $3,731

Equity-method investments8,123 11,637

Total long-term investments and equity-method investments$11,613 $15,368

Held-to-maturity cash equivalents$250 $207

(a)Represent money market funds primarily invested in U.S. Treasury and government debt.

(b)Represent investments in the life sciences sector.

Debt Securities

Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:

March 31, 2024December 31, 2023

Gross UnrealizedContractual or Estimated Maturities (in Years)Gross Unrealized

(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1

to 5Over 5Amortized CostGainsLossesFair Value

Available-for-sale debt securities

Government and agency non-U.S.

$5,414 $2 $(71)$5,345 $5,214 $131 $ $953 $2 $(14)$941

Government and agency U.S.

1,958 1,958 1,958 2,601 2,601

Corporate and other1,057 (6)1,051 1,045 6 1,006 4 (2)1,007

Held-to-maturity debt securities

Time deposits and other

705 705 665 27 13 561 561

Government and agency non-U.S.

100 100 95 4 1 4 4

Total debt securities$9,234 $2 $(78)$9,159 $8,976 $168 $14 $5,126 $6 $(16)$5,115

Any expected credit losses to these portfolios would be immaterial to our financial statements.

Equity Securities

The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:

Three Months Ended

(MILLIONS)March 31,

2024April 2,

2023

Net (gains)/losses recognized during the period on equity securities(a)

$(25)$451

Less: Net (gains)/losses recognized during the period on equity securities sold during the period(214)(33)

Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)

$188 $485

(a)Reported in Other (income)/deductions net. See Note 4.

18

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(b)Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of March 31, 2024, there were cumulative impairments and downward adjustments of $293 million and upward adjustments of $212 million. Impairments, downward and upward adjustments were not material to our operations in the first quarters of 2024 and 2023.

C. Short-Term Borrowings

Short-term borrowings include: